Revolutionize the delivery of RNA & protein
We create unique therapeutic bacteria for unmet patient needs. Our therapeutic focus includes pancreatic cancer and other solid tumors, as well as genetic disorders. Industry collaboration is an important pillar of our strategy.
Redbiotec News
BIO Digital 2020
Date: June 8-12, 2020 At a time when collaboration is more vital than ever, the Redbiotec team looks forward [...]
Recent interview with Mergermarket, Acuris
As Redbiotec prepares for a Series A financing round to take the most advanced asset - immunotherapy for HSV2-associated genital [...]
Analysis of Redbiotec by In Vivo (Informa Pharma Intelligence)
Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria Redbiotec has reached a new inflection point as it progresses two key [...]
Redbiotec Signs Collaboration Agreement with Large-Cap Pharma to Develop Targeted Living Medicines
Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will [...]